Quinapril 40mg tablets

Pays: Royaume-Uni

Langue: anglais

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingrédients actifs:

Quinapril hydrochloride

Disponible depuis:

Teva UK Ltd

Code ATC:

C09AA06

DCI (Dénomination commune internationale):

Quinapril hydrochloride

Dosage:

40mg

forme pharmaceutique:

Oral tablet

Mode d'administration:

Oral

classe:

No Controlled Drug Status

Type d'ordonnance:

Valid as a prescribable product

Descriptif du produit:

BNF: 02050501; GTIN: 5017007359555

Notice patient

READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING
THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or
pharmacist.
•
This medicine has been prescribed for you only. Do
not pass it on to others. It may harm them, even if
their signs of illness are the same as yours.
•
If you get any of the side effects talk to your doctor
or pharmacist. This includes any possible side
effects not listed in this leaflet. See section 4..
1. WHAT QUINAPRIL IS AND WHAT IT IS USED FOR
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE QUINAPRIL
3. HOW TO TAKE QUINAPRIL
4. POSSIBLE SIDE EFFECTS
5. HOW TO STORE QUINAPRIL
6. CONTENTS OF THE PACK AND OTHER INFORMATION
WHAT QUINAPRIL IS AND WHAT IT IS USED
FOR
Quinapril belongs to a group of drugs called
Angiotensin Converting Enzyme (ACE) Inhibitors,
which are vasodilators (drugs which widen the blood
vessels, reduce blood pressure and make it easier for
the heart to pump blood around the body).
Quinapril is used to treat:
•
high blood pressure
•
congestive heart failure (a condition where the heart
no longer pumps blood as effectively as it should).
WHAT YOU NEED TO KNOW BEFORE YOU
TAKE QUINAPRIL
DO NOT TAKE QUINAPRIL AND CONTACT YOUR DOCTOR
IMMEDIATELY IF YOU :
•
are allergic to quinapril or any of the other
ingredients of this medicine (listed in
•
section 6). Signs of allergic reaction include itching,
a rash on the skin or difficulty in
•
breathing
•
are more than 3 months pregnant. (It is also better
to avoid quinapril in early
•
pregnancy- see Pregnancy section below)
•
have a condition called angioneurotic oedema (a
swelling of the face, tongue or throat
•
which causes difficulty breathing)
•
have aortic stenosis (narrowing ofthe main blood
vessel from the heart).
•
have kidney disease
•
have diabetes or impaired kidney function and you
are treated with a blood pressure
•
lowering medicine containing aliskiren
•
have taken or are

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Quinapril 40 mg Film-coated Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 40 mg quinapril (as quinapril
hydrochloride).
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Film-coated tablets
Yellow, oval film-coated tablets debossed “40” on one side and
scoreline on the
other.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of essential hypertension
Treatment of congestive heart failure
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Adults
For oral use.
The dose should be individualised.
For the different dosage regimens, appropriate strengths of quinapril
are available.
ESSENTIAL HYPERTENSION
Monotherapy
:_ _
The recommended initial dosage is 10 mg once daily in hypertension.
Depending
upon
clinical
response, patient's
dosage
may
be
titrated
(by
doubling
the dose
allowing adequate timefor dosage adjustment) to a maintenance dosage
of 20 to 40
mg/day given as a single dose or divided into 2 doses. Long-term
control is
maintained in most patients with a single daily dosage regimen.
Patients have been treated with dosages up to 80 mg/day. Take either
with or without food. The dose should always be taken at about the
same time of day
to help increase compliance.
Concomitant Diuretics:
In order to determine if excess hypotension will occur, an initial
dosage of 2.5 mg of
Quinapril is recommended in patients who are being treated with a
diuretic. After this
the dosage of Quinapril should be titrated (as described above) to the
optimal
response (see sections 4.3, 4.4, 4.5 and 5.1.)
CONGESTIVE HEART FAILURE
In order to closely monitor patients for symptomatic hypotension, a
single 2.5 mg
initial dosage is recommended. After this, patients should be titrated
to an effective
dose: (up to 40 mg/day) given in 1 or 2 doses with concomitant
diuretic and/or
cardiac glycoside therapy. Patients are usually maintained effectively
on doses of 10-
20 mg/day given with concomitant therapy